[go: up one dir, main page]

CY1116929T1 - Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β - Google Patents

Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β

Info

Publication number
CY1116929T1
CY1116929T1 CY20141100689T CY141100689T CY1116929T1 CY 1116929 T1 CY1116929 T1 CY 1116929T1 CY 20141100689 T CY20141100689 T CY 20141100689T CY 141100689 T CY141100689 T CY 141100689T CY 1116929 T1 CY1116929 T1 CY 1116929T1
Authority
CY
Cyprus
Prior art keywords
protein kinase
compounds
pyrrolo
kinase inhibitors
pyrimidine derivatives
Prior art date
Application number
CY20141100689T
Other languages
English (en)
Inventor
Paul David Johnson
Andrew Leach
Richard William Arthur Luke
Zbigniew Stanley Matusiak
Jeffrey James Morris
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116929(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1116929T1 publication Critical patent/CY1116929T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η εφεύρεση σχετίζεται με μία νέα ομάδα χημικών ενώσεων του Τύπου (Ι) ή άλατα αυτών: όπου τα Υ, Ζ1, Ζ2, R1, R4, R5 και το n είναι, όπως περιγράφεται στην παρούσα προδιαγραφή, κάτι το οποίο θα μπορούσε να είναι χρήσιμο στην θεραπευτική αντιμετώπιση ή την πρόληψη μίας ασθένειας ή μίας ιατρικής πάθησης η οποία διαμεσολαβείται μέσω της πρωτεϊνικής κινάσης Β (ΡΚΒ), όπως είναι ο καρκίνος. Η εφεύρεση σχετίζεται, επίσης, με φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν τις εν λόγω χημικές ενώσεις, μεθόδους της θεραπευτικής αντιμετώπισης των ασθενειών οι οποίες διαμεσολαβούνται μέσω ΡΚΒ με την χρήση των εν λόγω χημικών ενώσεων και με μεθόδους για την παρασκευή των χημικών ενώσεων του Τύπου (Ι).
CY20141100689T 2007-10-11 2014-08-28 Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β CY1116929T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97919207P 2007-10-11 2007-10-11
US4786208P 2008-04-25 2008-04-25
EP08806741.8A EP2201012B1 (en) 2007-10-11 2008-10-09 Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors

Publications (1)

Publication Number Publication Date
CY1116929T1 true CY1116929T1 (el) 2017-04-05

Family

ID=40251789

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100689T CY1116929T1 (el) 2007-10-11 2014-08-28 Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β

Country Status (43)

Country Link
US (8) US8101623B2 (el)
EP (1) EP2201012B1 (el)
JP (2) JP4705695B2 (el)
KR (1) KR101494734B1 (el)
CN (1) CN101861321B (el)
AR (1) AR068846A1 (el)
AU (1) AU2008309383B2 (el)
BR (1) BRPI0818533B8 (el)
CA (1) CA2701057C (el)
CL (1) CL2008003023A1 (el)
CO (1) CO6270328A2 (el)
CR (1) CR11359A (el)
CU (1) CU23886B1 (el)
CY (1) CY1116929T1 (el)
DK (1) DK2201012T3 (el)
DO (1) DOP2010000103A (el)
EA (1) EA018512B1 (el)
ES (1) ES2522365T3 (el)
FI (1) FIC20240039I1 (el)
FR (1) FR24C1046I1 (el)
GT (1) GT201000082A (el)
HK (1) HK1143154A1 (el)
HN (1) HN2010000653A (el)
HR (1) HRP20140807T1 (el)
HU (1) HUS2400038I1 (el)
IL (1) IL204721A (el)
ME (1) ME01999B (el)
MX (1) MX2010003927A (el)
MY (1) MY150059A (el)
NI (1) NI201000050A (el)
NL (1) NL301299I2 (el)
NO (1) NO2024050I1 (el)
NZ (1) NZ585261A (el)
PE (2) PE20090964A1 (el)
PL (1) PL2201012T3 (el)
PT (1) PT2201012E (el)
RS (1) RS53552B1 (el)
SA (1) SA08290625B1 (el)
SI (1) SI2201012T1 (el)
TW (1) TWI453021B (el)
UY (1) UY31384A1 (el)
WO (1) WO2009047563A1 (el)
ZA (1) ZA201002318B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ES2878130T3 (es) 2006-04-25 2021-11-18 Astex Therapeutics Ltd Derivados de purina y deazapurina como compuestos farmacéuticos
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
EA018512B1 (ru) 2007-10-11 2013-08-30 Астразенека Аб Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
WO2011002772A1 (en) * 2009-06-29 2011-01-06 Oncotherapy Science, Inc. Imidazopyridine derivatives and pbk inhibitors containing the same
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
PH12013502048B1 (en) * 2011-04-01 2018-07-11 Astrazeneca Ab Therapeutic treatment
AU2012321110B2 (en) * 2011-11-30 2014-10-23 Astrazeneca Ab Combination treatment
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
AP2015008604A0 (en) 2013-01-23 2015-07-31 Astrazeneca Ab Chemical compounds
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
JP6295578B2 (ja) * 2013-09-30 2018-03-20 凸版印刷株式会社 反応容器、核酸解析装置、および核酸解析方法
EP3052097A1 (en) * 2013-10-01 2016-08-10 Novartis AG Combination
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2901711T3 (es) 2014-02-13 2022-03-23 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
CA2939081C (en) 2014-02-13 2023-08-15 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
MY173661A (en) * 2014-05-28 2020-02-14 Astrazeneca Ab Processes for the preparation of azd5363 and novel intermediate used therein
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
PH12017501817B1 (en) 2015-04-03 2023-06-16 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
TW201726140A (zh) * 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
CR20180553A (es) 2016-04-22 2019-02-01 Incyte Corp Formulaciones de un inhibidor de lsd1
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP4021450A1 (en) 2019-08-26 2022-07-06 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
AU2020381240C1 (en) 2019-11-04 2024-02-15 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies
US20240051964A1 (en) * 2021-01-04 2024-02-15 Teva Pharmaceuticals International Gmbh Solid state forms of capivasertib and process for preparation thereof
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CN114601836B (zh) * 2022-04-12 2022-12-06 四川大学华西医院 一种akt抑制剂在制备治疗乳腺癌的药物中的应用
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024104561A1 (en) 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax
WO2024245953A1 (en) 2023-05-26 2024-12-05 Astrazeneca Ab Pharmaceutical compositions
TW202448458A (zh) 2023-06-02 2024-12-16 美商亞文納營運公司 雌激素受體降解劑與ａｋｔ抑制劑之組合

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (el) 1963-04-04 1900-01-01
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU6111298A (en) 1997-02-12 1998-09-08 Samir M. Hanash Protein markers for lung cancer and use thereof
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EA200000098A1 (ru) 1997-08-05 2000-08-28 Пфайзер Продактс Инк. 4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
SK18542000A3 (sk) 1998-06-04 2001-12-03 Abbott Laboratories Protizápalové zlúčeniny inhibujúce bunkovú adhéziu
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
BR0015203A (pt) 1999-11-05 2002-07-16 Astrazeneca Ab Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CN1329390C (zh) 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0111561A (pt) 2000-06-26 2003-09-09 Pfizer Prod Inc Composto pirrolo[2,3-d] pirimidina como agentes imunossupressores
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
KR100602929B1 (ko) 2000-08-31 2006-07-20 에프. 호프만-라 로슈 아게 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
YU42703A (sh) 2000-12-01 2006-03-03 Osi Pharmaceuticals Inc. Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
IL162884A0 (en) 2002-01-07 2005-11-20 Eisai Co Ltd Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
PT1522314E (pt) * 2002-06-26 2014-06-05 Ono Pharmaceutical Co Medicamentos para doenças causadas pela contracção ou dilatação vascular
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
AU2003302657B8 (en) * 2002-12-04 2009-12-03 Eisai R&D Management Co., Ltd. Fused 1,3-dihydroimidazole ring compounds
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
CN1720246A (zh) 2003-04-21 2006-01-11 捷克共和国乌斯塔夫化学与生物化学研究院 (嘌呤－6－基)氨基酸及其制备方法
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
JP4792974B2 (ja) * 2003-12-25 2011-10-12 小野薬品工業株式会社 アゼチジン環化合物およびその医薬
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) * 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
ES2878130T3 (es) 2006-04-25 2021-11-18 Astex Therapeutics Ltd Derivados de purina y deazapurina como compuestos farmacéuticos
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
WO2007125320A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
EA018512B1 (ru) 2007-10-11 2013-08-30 Астразенека Аб Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в

Also Published As

Publication number Publication date
NI201000050A (es) 2011-12-22
US20240109902A1 (en) 2024-04-04
CN101861321B (zh) 2013-02-06
KR20100101077A (ko) 2010-09-16
IL204721A (en) 2013-10-31
BRPI0818533A2 (pt) 2017-06-06
EA201000552A1 (ru) 2010-12-30
HK1143154A1 (en) 2010-12-24
PT2201012E (pt) 2014-09-04
EA018512B1 (ru) 2013-08-30
JP2011157364A (ja) 2011-08-18
EP2201012A1 (en) 2010-06-30
BRPI0818533B8 (pt) 2021-05-25
SA08290625B1 (ar) 2012-02-12
UY31384A1 (es) 2009-05-29
NO2024050I1 (no) 2024-11-18
FR24C1046I1 (fr) 2025-01-10
NZ585261A (en) 2011-10-28
IL204721A0 (en) 2010-11-30
AU2008309383A1 (en) 2009-04-16
FIC20240039I1 (fi) 2024-11-12
CN101861321A (zh) 2010-10-13
KR101494734B1 (ko) 2015-02-26
ES2522365T3 (es) 2014-11-14
CA2701057A1 (en) 2009-04-16
US10059714B2 (en) 2018-08-28
TW200927128A (en) 2009-07-01
HN2010000653A (es) 2013-03-18
US20120190679A1 (en) 2012-07-26
AR068846A1 (es) 2009-12-09
AU2008309383B2 (en) 2012-04-19
US20170057969A1 (en) 2017-03-02
WO2009047563A1 (en) 2009-04-16
CU20100062A7 (es) 2011-10-05
US11236095B2 (en) 2022-02-01
US11760760B2 (en) 2023-09-19
PE20130152A1 (es) 2013-03-17
CR11359A (es) 2010-07-15
PL2201012T3 (pl) 2014-11-28
US8101623B2 (en) 2012-01-24
JP2011500547A (ja) 2011-01-06
NL301299I2 (nl) 2024-12-11
US20220220116A1 (en) 2022-07-14
JP4705695B2 (ja) 2011-06-22
US20150182531A1 (en) 2015-07-02
PE20090964A1 (es) 2009-08-15
DOP2010000103A (es) 2010-05-31
MX2010003927A (es) 2010-04-30
CL2008003023A1 (es) 2009-11-27
EP2201012B1 (en) 2014-06-25
JP5330430B2 (ja) 2013-10-30
CA2701057C (en) 2015-03-24
US20180312516A1 (en) 2018-11-01
ME01999B (me) 2015-05-20
US20200239483A1 (en) 2020-07-30
DK2201012T3 (da) 2014-09-08
BRPI0818533B1 (pt) 2020-12-01
ZA201002318B (en) 2012-09-26
TWI453021B (zh) 2014-09-21
RS53552B1 (en) 2015-02-27
GT201000082A (es) 2015-03-10
US20090163524A1 (en) 2009-06-25
SI2201012T1 (sl) 2014-10-30
CU23886B1 (es) 2013-04-19
CO6270328A2 (es) 2011-04-20
MY150059A (en) 2013-11-29
US12252495B2 (en) 2025-03-18
US9492453B2 (en) 2016-11-15
HRP20140807T1 (hr) 2014-11-21
HUS2400038I1 (hu) 2024-12-28
US10654855B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
CO6290714A2 (es) Compuestos organicos
DE602007013252D1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CY1112809T1 (el) Παραγωγα της ινδολ-2-ονης δισυποκατεστημενα στη θεση 3, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
EA200801425A1 (ru) Диазепиноны
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
UA93198C2 (ru) Производные пиразола, способ их получения, их применения, фармацевтическая композиция (варианты) и способ лечения злокачественного новообразования (варианты)
CY1114281T1 (el) Ενωσεις πυριδινονης
UA93197C2 (ru) Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)
CY1112245T1 (el) Ετεροαλκυλ συνδεδεμενα παραγωγα πυριμιδινης